ONO PHARMA UK LTD
↗London, United Kingdom
ONO PHARMA UK LTD. (OPUK) is the European subsidiary of Ono Pharmaceutical Co., Ltd., a major R&D-oriented Japanese pharmaceutical company headquartered in Osaka. Established in 1998, OPUK has served as the company's innovation hub in Europe, focusing on therapeutic development in oncology, immunology, and neurology. The company commits to strategic partnerships with leading academic institutions and biotech organizations across the UK and Europe to advance drug discovery and development. As of March 2025, OPUK employs approximately 28 staff members and operates as a center for research collaboration activities following the company's reorganization of US and European operations.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Oncology, Immunology, Neurology
SIZE & FINANCIALS
Employees:1-50 (OPUK); 1001-5000 (parent company)
Revenue:¥487.0 billion (FY2024 consolidated)
Founded:1998
Ownership:subsidiary
Status:operating
STOCK
Exchange:Tokyo Stock Exchange (TSE)
Ticker:4528
Market Cap:¥797.2 billion (~$7.97B USD equivalent)
PIPELINE
Stage:Phase 1 through Commercial
Lead Drug Stage:Commercial (QINLOCK, ROMVIMZA, FORXIGA, OPDIVO combination therapies)
Modalities:Small molecule, Monoclonal antibodies (mAb), RNA-targeted therapeutics
Active Trials:20
Trial Phases:Phase 1: 3 | Phase 2: 5 | Phase 3: 4 | Phase 4: 8
FDA Approvals:2
EMA Approvals:1
CORPORATE STRUCTURE
Parent Company:Ono Pharmaceutical Co., Ltd. (Osaka, Japan)
Subsidiaries:ONO PHARMA USA, INC. (Cambridge, Massachusetts) - being integrated into Deciphera, Deciphera Pharmaceuticals, LLC (acquired April 2024 for $2.4B)
Key Partnerships:Ionis Pharmaceuticals - Sapablursen global license agreement (2025, $280M upfront + up to $660M milestones), Harvard University - Strategic 5-year alliance across oncology, immunology, neurology (2024), University of Oxford - Drug discovery collaboration agreement (2024), Monash University - GPCR antibody development collaboration (2024), UK DRI (UK Dementia Research Institute) - Neurodegeneration funding initiative (2023), Reborna Biosciences - RNA-targeting drug discovery collaboration (2025), Congruence Therapeutics - Oncology small molecule correctors collaboration (2024), NEX-I - NXI-101 antibody licensing for cancer immunotherapy (2024), Cancer Research UK & LifeArc - Immuno-oncology partnership with multimillion-pound investment, PRISM - Oncology drug discovery joint research and licensing (2024), Seikagaku - Gel-One co-development for osteoarthritis in Japan (2025)
COMPETITION
Position:Challenger/Emerging Leader in rare oncology; Established player in Japan
Competitors:Daiichi Sankyo (TURALIO for TGCT), Merck KGaA (pimicotinib for TGCT), Bristol Myers Squibb (OPDIVO), Roche/Genentech (immuno-oncology), Celgene (rare diseases, acquired by Bristol Myers Squibb), Takeda Pharmaceutical, Sumitomo Pharma
LEADERSHIP
Key Executives:
Gyo Sagara - Chief Executive Officer and Chairman
Toichi Takino - President and Chief Operating Officer
Tsujinaka - Executive Vice President
Kunihiko Ito - President and CEO, ONO PHARMA USA, INC.
Hiromu Habashita, Ph.D. - Corporate Officer / Deputy Executive Director, Discovery & Research
Shinji Takai, M.D., Ph.D. - Corporate Officer / Executive Director, Clinical Development
LINKS
Website:ono-uk.co.uk
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with ONO PHARMA UK LTD. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.